Journal of Neuroimmune Pharmacology

, Volume 9, Issue 2, pp 92–101

Fibroblast Growth Factor-2 Signaling in Neurogenesis and Neurodegeneration

INVITED REVIEW

DOI: 10.1007/s11481-013-9501-5

Cite this article as:
Woodbury, M.E. & Ikezu, T. J Neuroimmune Pharmacol (2014) 9: 92. doi:10.1007/s11481-013-9501-5

Abstract

Fibroblast growth factor-2 (FGF2), also known as basic FGF, is a multi-functional growth factor. One of the 22-member FGF family, it signals through receptor tyrosine kinases encoding FGFR1-4. FGF2 activates FGFRs in cooperation with heparin or heparin sulfate proteoglycan to induce its pleiotropic effects in different tissues and organs, which include potent angiogenic effects and important roles in the differentiation and function of the central nervous system (CNS). FGF2 is crucial to development of the CNS, which explains its importance in adult neurogenesis. During development, high levels of FGF2 are detected from neurulation onwards. Moreover, developmental expression of FGF2 and its receptors is temporally and spatially regulated, concurring with development of specific brain regions including the hippocampus and substantia nigra pars compacta. In adult neurogenesis, FGF2 has been implicated based on its expression and regulation of neural stem and progenitor cells in the neurogenic niches, the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampal dentate gyrus. FGFR1 signaling also modulates inflammatory signaling through the surface glycoprotein CD200, which regulates microglial activation. Because of its importance in adult neurogenesis and neuroinflammation, manipulation of FGF2/FGFR1 signaling has been a focus of therapeutic development for neurodegenerative disorders, such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease and traumatic brain injury. Novel strategies include intranasal administration of FGF2, administration of an NCAM-derived FGFR1 agonist, and chitosan-based nanoparticles for the delivery of FGF2 in pre-clinical animal models. In this review, we highlight current research towards therapeutic interventions targeting FGF2/FGFR1 in neurodegenerative disorders.

Keywords

Fibroblast growth factor Neurogenesis Alzheimer's disease Clinical trial Neuroinflammation CD200 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Graduate Program in NeuroscienceBoston University School of MedicineBostonUSA
  2. 2.Departments of Pharmacology and Experimental TherapeuticsBoston University School of MedicineBostonUSA
  3. 3.Department of NeurologyBoston University School of MedicineBostonUSA

Personalised recommendations